[1] Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., & Barsouk, A. (2021). Epidemiology of Melanoma. Medical Sciences : Open Access Journal, 9(4), 63. https://doi.org/10.3390/medsci9040063

[2] Shinzawa, K., Matsumoto, S., Sada, R., Harada, A., Saitoh, K., Kato, K., Ikeda, S., Hirayama, A., Yokoi, K., Tanemura, A., Nimura, K., Ikawa, M., Soga, T., & Kikuchi, A. (2023). GREB1 isoform 4 is specifically transcribed by MITF and required for melanoma proliferation. Oncogene, 42(42), 3142– 3156. https://doi.org/10.1038/s41388-023-02803-6

[3] Sumantran, V. N., Mishra, P., & Sudhakar, N. (2015). Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression. Indian Journal of Biochemistry & Biophysics, 52(2), 125–131.

[4] Jemal, A., Saraiya, M., Patel, P., Cherala, S. S., Barnholtz-Sloan, J., Kim, J., Wiggins, C. L., & Wingo, P. A. (2011). Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. Journal of the American Academy of Dermatology, 65(5 Suppl 1), S17–25.e1-3.

[5] Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590

[6] Leonardi, G. C., Falzone, L., Salemi, R., Zanghì, A., Spandidos, D. A., Mccubrey, J. A., Candido, S., & Libra, M. (2018). Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology, 52(4), 1071–1080. https://doi.org/10.3892/ijo.2018.4287

[7] Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., III, Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., Valiga, A. A., Morissette, R., McDonnell, N. B., Ferrucci, L., Kossenkov, A. V., Meeth, K., Tang, H. Y., Yin, X., Wood, W. H., III, . . . Weeraratna, A. T. (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532(7598), 250–254. https://doi.org/10.1038/nature17392

[8] Macdonald, J. B., Dueck, A. C., Gray, R. J., Wasif, N., Swanson, D. L., Sekulic, A., & Pockaj, B. A. (2011). Malignant melanoma in the elderly: Different regional disease and poorer prognosis. Journal of Cancer, 2(2), 538–543. https://doi.org/10.7150/jca.2.538

[9] Arozarena, I., & Wellbrock, C. (2017). Targeting invasive properties of melanoma cells. The FEBS Journal, 284(14), 2148–2162. https://doi.org/10.1111/febs.14040

[10] Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., Rodriguez, J., Brunton, H., Kmarashev, J., Levesque, M. P., Dummer, R., Frederick, D. T., Andrews, M. C., Cooper, Z. A., Flaherty, K. T., . . . Wellbrock, C. (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9(8), 1011–1029. https://doi.org/10.15252/emmm.201607156

[11] Campbell, N. R., Rao, A., Hunter, M. V., Sznurkowska, M. K., Briker, L., Zhang, M., Baron, M., Heilmann, S., Deforet, M., Kenny, C., Ferretti, L. P., Huang, T. H., Perlee, S., Garg, M., Nsengimana, J., Saini, M., Montal, E., Tagore, M., Newton-Bishop, J., . . . White, R. M. (2021). Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation. Developmental Cell, 56(20), 2808–2825.e10. https://doi.org/10.1016/j.devcel.2021.08.018

[12] Sharma, B., & Agnihotri, N. (2019). Role of cholesterol homeostasis and its efflux pathways in cancer progression. The Journal of Steroid Biochemistry and Molecular Biology, 191, 105377. https://doi.org/10.1016/j.jsbmb.2019.105377

[13] Riscal, R., Skuli, N., & Simon, M. C. (2019). Even cancer cells watch their cholesterol! Molecular Cell, 76(2), 220–231. https://doi.org/10.1016/j.molcel.2019.09.008

[14] Schallreuter, K. U., Hasse, S., Rokos, H., Chavan, B., Shalbaf, M., Spencer, J. D., & Wood, J. M. (2009). Cholesterol regulates melanogenesis in human epidermal melanocytes and melanoma cells. Experimental Dermatology, 18(8), 680–688. https://doi.org/10.1111/j.1600-0625.2009.00850.x

[15] Luo, J., Yang, H., & Song, B. L. (2020). Mechanisms and regulation of cholesterol homeostasis. Nature Reviews. Molecular Cell Biology, 21(4), 225–245. https://doi.org/10.1038/s41580-019-0190-7

[16] Rogers, M. A., Liu, J., Song, B. L., Li, B. L., Chang, C. C., & Chang, T. Y. (2015). Acyl-CoA: Cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. The Journal of Steroid Biochemistry and Molecular Biology, 151, 102–107. https://doi.org/10.1016/j.jsbmb.2014.09.008

[17] Xia, W., Wang, H., Zhou, X., Wang, Y., Xue, L., Cao, B., & Song, J. (2023). The role of cholesterol metabolism in tumor therapy, from bench to bed. Frontiers in Pharmacology, 14, 928821. https://doi.org/10.3389/fphar.2023.928821

[18] Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016). Lipid metabolic reprogramming in cancer cells. Oncogenesis, 5(1), e189. https://doi.org/10.1038/oncsis.2015.49

[19] Huang, B., Song, B. L., & Xu, C. (2020). Cholesterol metabolism in cancer: Mechanisms and therapeutic opportunities. Nature Metabolism, 2(2), 132–141. https://doi.org/10.1038/s42255-020-0174-0

[20] Yamauchi, Y., Furukawa, K., Hamamura, K., & Furukawa, K. (2011). Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: Induction of the lipogenic pathway by a melanoma antigen. Cancer Research, 71(14), 4989–4997. https://doi.org/10.1158/0008-5472.CAN-10-4108

[21] Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016). The role of cholesterol in cancer. Cancer Research, 76(8), 2063–2070. https://doi.org/10.1158/0008- 5472.CAN-15-2613

[22] Tian, W., Pang, W., Ge, Y., He, X., Wang, D., Li, X., Hou, H., Zhou, D., Feng, S., Chen, Z., & Yang, Y. (2018). Hepatocyte-generated 27-hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha. Journal of Cellular Biochemistry, 119(3), 2929–2938. https://doi.org/10.1002/jcb.26498

[23] Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014). Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell, 156(5), 986–1001. https://doi.org/10.1016/j.cell.2014.01.038

[24] Restivo, G., Diener, J., Cheng, P. F., Kiowski, G., Bonalli, M., Biedermann, T., Reichmann, E., Levesque, M. P., Dummer, R., & Sommer, L. (2018). Publisher correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma. Nature Communications, 9(1), 314. https://doi.org/10.1038/s41467-018-02850-8

[25] Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., & Krieger, M. (1996). Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science, 271(5248), 518–520. https://doi.org/10.1126/science.271.5248.518

[26] Kinslechner, K., Schörghofer, D., Schütz, B., Vallianou, M., Wingelhofer, B., Mikulits, W., Röhrl, C., Hengstschläger, M., Moriggl, R., Stangl, H., & Mikula, M. (2018). Malignant phenotypes in metastatic melanoma are governed by SR-BI and its association with glycosylation and STAT5 activation. Molecular Cancer Research, 16(1), 135–146. https://doi.org/10.1158/1541-7786.MCR-17-0292

[27] Hoek, K. S., Schlegel, N. C., Eichhoff, O. M., Widmer, D. S., Praetorius, C., Einarsson, S. O., Valgeirsdottir, S., Bergsteinsdottir, K., Schepsky, A., Dummer, R., & Steingrimsson, E. (2008). Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell & Melanoma Research, 21(6), 665–676. https://doi.org/10.1111/j.1755-148X.2008.00505.x

[28] Li, Y. C., Park, M. J., Ye, S. K., Kim, C. W., & Kim, Y. N. (2006). Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. American Journal of Pathology, 168(4), 1107–1118. https://doi.org/10.2353/ajpath.2006.050959

[29] Wang, R., Bi, J., Ampah, K. K., Ba, X., Liu, W., & Zeng, X. (2013). Lipid rafts control human melanoma cell migration by regulating focal adhesion disassembly. Biochimica et Biophysica Acta, 1833(12), 3195–3205. https://doi.org/10.1016/j.bbamcr.2013.09.007

[30] Costa, G. A., de Souza, S. B., da Silva Teixeira, L. R., Okorokov, L. A., Arnholdt, A. C. V., Okorokova- Façanha, A. L., & Façanha, A. R. (2018). Tumor cell cholesterol depletion and V-ATPase inhibition as an inhibitory mechanism to prevent cell migration and invasiveness in melanoma. Biochimica et Biophysica Acta: General Subjects, 1862(3), 684– 691. https://doi.org/10.1016/j.bbagen.2017.12.006

[31] Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011). Dysregulated pH: A perfect storm for cancer progression. Nature Reviews Cancer, 11(9), 671–677. https://doi.org/10.1038/nrc3110

[32] Caldieri, G., Giacchetti, G., Beznoussenko, G., Attanasio, F., Ayala, I., & Buccione, R. (2009). Invadopodia biogenesis is regulated by caveolin-mediated modulation of membrane cholesterol levels. Journal of Cellular and Molecular Medicine, 13(8B), 1728–1740. https://doi.org/10.1111/j.1582- 4934.2008.00568.x

[33] Ayee, M. A., & Levitan, I. (2016). Paradoxical impact of cholesterol on lipid packing and cell stiffness. Frontiers in Bioscience (Landmark Edition), 21(6), 1245–1259. https://doi.org/10.2741/4454

[34] Zalba, S., & Ten Hagen, T. L. (2017). Cell membrane modulation as adjuvant in cancer therapy. Cancer Treatment Reviews, 52, 48–57. https://doi.org/10.1016/j.ctrv.2016.10.008

[35] Zhao, W., Prijic, S., Urban, B. C., Tisza, M. J., Zuo, Y., Li, L., Tan, Z., Chen, X., Mani, S. A., & Chang, J. T. (2016). Candidate antimetastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity. Cancer Research, 76(7), 2037–2049. https://doi.org/10.1158/0008-5472.CAN-15-1970

[36] Elborn, J. S. (2016). Cystic fibrosis. Lancet, 388(10059), 2519–2531. https://doi.org/10.1016/S0140-6736(16)00576-6

[37] Walker, F. O. (2007). Huntington’s disease. Lancet, 369(9557), 218–228. https://doi.org/10.1016/S0140- 6736(07)60111-1

[38] Peltonen, L., Perola, M., Naukkarinen, J., & Palotie, A. (2006). Lessons from studying monogenic disease for common disease. Human Molecular Genetics, 15(Spec No 1, suppl_1), R67–R74. https://doi.org/10.1093/hmg/ddl060

[39] Petersen, B. S., Fredrich, B., Hoeppner, M. P., Ellinghaus, D., & Franke, A. (2017). Opportunities and challenges of whole-genome and - exome sequencing. BMC Genetics, 18(1), 14. https://doi.org/10.1186/s12863-017-0479-5

[40] Botstein, D., & Risch, N. (2003). Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease. Nature Genetics, 33(Suppl), 228–237. https://doi.org/10.1038/ng1090

[41] Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E. E., Bamshad, M., Nickerson, D. A., & Shendure, J. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. Nature, 461(7261), 272–276. https://doi.org/10.1038/nature08250

[42] Hodges, E., Xuan, Z., Balija, V., Kramer, M., Molla, M. N., Smith, S. W., Middle, C. M., Rodesch, M. J., Albert, T. J., Hannon, G. J., & McCombie, W. R. (2007). Genome-wide in situ exon capture for selective resequencing. Nature Genetics, 39(12), 1522–1527. https://doi.org/10.1038/ng.2007.42

[43] Jennings, L. J., Arcila, M. E., Corless, C., Kamel- Reid, S., Lubin, I. M., Pfeifer, J., Temple-Smolkin, R. L., Voelkerding, K. V., & Nikiforova, M. N. (2017). Guidelines for validation of next-generation sequencing-based oncology panels: A joint consensus recommendation of the association for molecular pathology and college of american pathologists. The Journal of Molecular Diagnostics, 19(3), 341– 365. https://doi.org/10.1016/j.jmoldx.2017.01.011

[44] Woolston, A. L., Hsiao, P. C., Kuo, P. H., Wang, S. H., Lien, Y. J., Liu, C. M., Hwu, H. G., Lu, T. P., Chuang, E. Y., Chang, L. C., Chen, C. H., Wu, J. Y., Tsuang, M. T., & Chen, W. J. (2017). Genetic loci associated with an earlier age at onset in multiplex schizophrenia. Scientific Reports, 7(1), 6486. https://doi.org/10.1038/s41598-017-06795-8

[45] Génin, E., Feingold, J., & Clerget-Darpoux, F. (2008). Identifying modifier genes of monogenic disease: Strategies and difficulties. Human Genetics, 124(4), 357–368. https://doi.org/10.1007/s00439-008-0560- 2

[46] Chiò, A., Mazzini, L., D’Alfonso, S., Corrado, L., Canosa, A., Moglia, C., Manera, U., Bersano, E., Brunetti, M., Barberis, M., Veldink, J. H., van den Berg, L. H., Pearce, N., Sproviero, W., McLaughlin, R., Vajda, A., Hardiman, O., Rooney, J., Mora, G., . . . Al-Chalabi, A. (2018). The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology, 91(7), e635–e642. https://doi.org/10.1212/WNL.0000000000005996

[47] Warr, A., Robert, C., Hume, D., Archibald, A., Deeb, N., & Watson, M. (2015). Exome Sequencing: Current and future perspectives. G3 (Bethesda, Md.), 5(8), 1543–1550. https://doi.org/10.1534/g3.115.018564

[48] Marian, A. J. (2014). Sequencing your genome: What does it mean? Methodist DeBakey Cardiovascular Journal, 10(1), 3–6. https://doi.org/10.14797/mdcj-10-1- 3

[49] Clark, M. J., Chen, R., Lam, H. Y., Karczewski, K. J., Chen, R., Euskirchen, G., Butte, A. J., & Snyder, M. (2011). Performance comparison of exome DNA sequencing technologies. Nature Biotechnology, 29(10), 908–914. https://doi.org/10.1038/nbt.1975

[50] Scatena, C., Murtas, D., & Tomei, S. (2021). Cutaneous melanoma classification: The importance of high-throughput genomic technologies. Frontiers in Oncology, 11, 635488. https://doi.org/10.3389/fonc.2021.635488

[51] Gonzaga-Jauregui, C., Lupski, J. R., & Gibbs, R. A. (2012). Human genome sequencing in health and disease. Annual Review of Medicine, 63, 35–61. https://doi.org/10.1146/annurev-med-051010-162644

[52] Teer, J. K., & Mullikin, J. C. (2010). Exome sequencing: The sweet spot before whole genomes. Human Molecular Genetics, 19(R2), R145–R151. https://doi.org/10.1093/hmg/ddq333

[53] Bashiardes, S., Veile, R., Helms, C., Mardis, E. R., Bowcock, A. M., & Lovett, M. (2005). Direct genomic selection. Nature Methods, 2(1), 63–69. https://doi.org/10.1038/nmeth0105-63

[54] Tadic, M., Kralj, S., Jagodic, M., Hanzel, D., & Makovec, D. (2014). Magnetic properties of novel superparamagnetic iron oxide nanoclusters and their peculiarity under annealing treatment. Applied Surface Science, 322, 255–264. https://doi.org/10.1016/j.apsusc.2014.09.181

[55] Marian, A. J. (2011). Medical DNA sequencing. Current Opinion in Cardiology, 26(3), 175–180. https://doi.org/10.1097/HCO.0b013e3283459857

[56] Olson, N. D., Lund, S. P., Colman, R. E., Foster, J. T., Sahl, J. W., Schupp, J. M., Keim, P., Morrow, J. B., Salit, M. L., & Zook, J. M. (2015). Best practices for evaluating single nucleotide variant calling methods for microbial genomics. Frontiers in Genetics, 6, 235. https://doi.org/10.3389/fgene.2015.00235

[57] Sanger, F., & Coulson, A. R. (1975). A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. Journal of Molecular Biology, 94(3), 441–448. https://doi.org/10.1016/0022- 2836(75)90213-2

[58] van Vliet, A. H. (2010). Next generation sequencing of microbial transcriptomes: Challenges and opportunities. FEMS Microbiology Letters, 302(1), 1– 7. https://doi.org/10.1111/j.1574-6968.2009.01767.x

[59] Kanrar, S., & Dhar, A. K. (2018). Complete genome sequence of a novel mutant strain of vibrio parahaemolyticus from Pacific White Shrimp (Penaeus vannamei). Genome Announcements, 6(24), e00497–18. https://doi.org/10.1128/genomeA.00497-18

[60] Guo, Y., Long, J., He, J., Li, C. I., Cai, Q., Shu, X. O., Zheng, W., & Li, C. (2012). Exome sequencing generates high quality data in non-target regions. BMC Genomics, 13, 194. https://doi.org/10.1186/1471- 2164-13-194

[61] Akintunde, O., Tucker, T., & Carabetta, V. J. (2023). The evolution of next-generation sequencing technologies. ArXiv.

[62] Buermans, H. P., & den Dunnen, J. T. (2014). Next generation sequencing technology: Advances and applications. Biochimica et Biophysica Acta, 1842(10), 1932–1941. https://doi.org/10.1016/j.bbadis.2014.06.015

[63] Nolan, D., & Carlson, M. (2016). Whole exome sequencing in pediatric neurology patients: Clinical implications and estimated cost analysis. Journal of Child Neurology, 31(7), 887–894. https://doi.org/10.1177/0883073815627880

[64] Salazar-García, L., Pérez-Sayáns, M., García-García, A., Carracedo, Á., Cruz, R., Lozano, A., Sobrino, B., & Barros, F. (2018). Whole exome sequencing approach to analysis of the origin of cancer stem cells in patients with head and neck squamous cell carcinoma. Journal of Oral Pathology & Medicine, 47(10), 938–944. https://doi.org/10.1111/jop.12771

[65] Cock, P. J., Fields, C. J., Goto, N., Heuer, M. L., & Rice, P. M. (2010). The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variants. Nucleic Acids Research, 38(6), 1767–1771. https://doi.org/10.1093/nar/gkp1137

[66] Bao, R., Huang, L., Andrade, J., Tan, W., Kibbe, W. A., Jiang, H., & Feng, G. (2014). Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing. Cancer Informatics, 13(Suppl 2), 67–82. https://doi.org/10.4137/CIN.S13779

[67] He, B., Zhu, R., Yang, H., Lu, Q., Wang, W., Song, L., Sun, X., Zhang, G., Li, S., Yang, J., Tian, G., Bing, P., & Lang, J. (2020). Assessing the impact of data preprocessing on analyzing next generation sequencing data. Frontiers in Bioengineering and Biotechnology, 8, 817. https://doi.org/10.3389/fbioe.2020.00817

[68] Das, S., Biswas, N. K., & Basu, A. (2023). Mapinsights: Deep exploration of quality issues and error profiles in high-throughput sequence data. Nucleic Acids Research, 51(14), e75–e75. https://doi.org/10.1093/nar/gkad539

[69] Meena, N., Mathur, P., Medicherla, K. M., & Suravajhala, P. A bioinformatics pipeline for whole exome sequencing: Overview of the processing and steps from raw data to downstream analysis. bioRxiv, 2017: p. 201145. https://doi.org/10.1101/201145

[70] Halim-Fikri, H., Syed-Hassan, S. R., Wan-Juhari, W. K., Assyuhada, M. G. S. N., Hernaningsih, Y., Yusoff, N. M., Merican, A. F., & Zilfalil, B. A. (2023). Central resources of variant discovery and annotation and its role in precision medicine. Asian Biomedicine: Research, Reviews and News, 16(6), 285–298. https://doi.org/10.2478/abm-2022-0032

[71] Xu, H., DiCarlo, J., Satya, R. V., Peng, Q., & Wang, Y. (2014). Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics, 15, 244. https://doi.org/10.1186/1471-2164-15-244

[72] Hartman, M. L., Sztiller-Sikorska, M., & Czyz, M. (2019). Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. Molecular Carcinogenesis, 58(4), 588–602. https://doi.org/10.1002/mc.22953

[73] Ferreira, P. G., Jares, P., Rico, D., Gómez-López, G., Martínez-Trillos, A., Villamor, N., Ecker, S., González- Pérez, A., Knowles, D. G., Monlong, J., Johnson, R., Quesada, V., Djebali, S., Papasaikas, P., López- Guerra, M., Colomer, D., Royo, C., Cazorla, M., Pinyol, M., . . . Guigó, R. (2014). Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 24(2), 212–226. https://doi.org/10.1101/gr.152132.112

[74] Shi, H., Zhou, Y., Jia, E., Pan, M., Bai, Y., & Ge, Q. (2021). Bias in RNA-seq library preparation: Current challenges and solutions. BioMed Research International, 2021, 6647597. https://doi.org/10.1155/2021/6647597

[75] Yassour, M., Kaplan, T., Fraser, H. B., Levin, J. Z., Pfiffner, J., Adiconis, X., Schroth, G., Luo, S., Khrebtukova, I., Gnirke, A., Nusbaum, C., Thompson, D. A., Friedman, N., & Regev, A. (2009). Ab initio construction of a eukaryotic transcriptome by massively parallel mRNA sequencing. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3264–3269. https://doi.org/10.1073/pnas.0812841106

[76] Maher, C. A., Palanisamy, N., Brenner, J. C., Cao, X., Kalyana-Sundaram, S., Luo, S., Khrebtukova, I., Barrette, T. R., Grasso, C., Yu, J., Lonigro, R. J., Schroth, G., Kumar-Sinha, C., & Chinnaiyan, A. M. (2009). Chimeric transcript discovery by paired-end transcriptome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 106(30), 12353–12358. https://doi.org/10.1073/pnas.0904720106

[77] Krishnakumar, S., Zheng, J., Wilhelmy, J., Faham, M., Mindrinos, M., & Davis, R. (2008). A comprehensive assay for targeted multiplex amplification of human DNA sequences. Proceedings of the National Academy of Sciences of the United States of America, 105(27), 9296–9301. https://doi.org/10.1073/pnas.0803240105

[78] Sugarbaker, D. J., Richards, W. G., Gordon, G. J., Dong, L., De Rienzo, A., Maulik, G., Glickman, J. N., Chirieac, L. R., Hartman, M. L., Taillon, B. E., Du, L., Bouffard, P., Kingsmore, S. F., Miller, N. A., Farmer, A. D., Jensen, R. V., Gullans, S. R., & Bueno, R. (2008). Transcriptome sequencing of malignant pleural mesothelioma tumors. Proceedings of the National Academy of Sciences of the United States of America, 105(9), 3521–3526. https://doi.org/10.1073/pnas.0712399105

[79] Zhang, H., He, L., & Cai, L. (2018). Transcriptome sequencing: RNA-Seq. Methods in Molecular Biology (Clifton, N.J.), 1754, 15–27. https://doi.org/10.1007/978-1-4939-7717-8_2

[80] Pilia, G., Chen, W. M., Scuteri, A., Orrú, M., Albai, G., Dei, M., Lai, S., Usala, G., Lai, M., Loi, P., Mameli, C., Vacca, L., Deiana, M., Olla, N., Masala, M., Cao, A., Najjar, S. S., Terracciano, A., Nedorezov, T., . . . Schlessinger, D. (2006). Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLOS Genetics, 2(8), e132. https://doi.org/10.1371/journal.pgen.0020132

[81] Rahalkar, A. R., & Hegele, R. A. (2008). Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum. Molecular Genetics and Metabolism, 93(3), 282–294. https://doi.org/10.1016/j.ymgme.2007.10.007

[82] Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., Fennell, T., Banks, E., Ambrogio, L., Cibulskis, K., Kernytsky, A., Gonzalez, E., Rudzicz, N., Engert, J. C., DePristo, M. A., . . . Kathiresan, S. (2010). Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. The New England Journal of Medicine, 363(23), 2220– 2227. https://doi.org/10.1056/NEJMoa1002926

[83] Lange, L. A., Hu, Y., Zhang, H., Xue, C., Schmidt, E. M., Tang, Z. Z., Bizon, C., Lange, E. M., Smith, J. D., Turner, E. H., Jun, G., Kang, H. M., Peloso, G., Auer, P., Li, K. P., Flannick, J., Zhang, J., Fuchsberger, C., Gaulton, K., . . . Willer, C. J., & the NHLBI Grand Opportunity Exome Sequencing Project. (2014). Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. American Journal of Human Genetics, 94(2), 233–245. https://doi.org/10.1016/j.ajhg.2014.01.010

[84] Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J. P., Nickerson, E., Auclair, D., Li, L., Place, C., Dicara, D., Ramos, A. H., Lawrence, M. S., Cibulskis, K., Sivachenko, A., Voet, D., Saksena, G., Stransky, N., Onofrio, R. C., . . . Chin, L. (2012). A landscape of driver mutations in melanoma. Cell, 150(2), 251–263. https://doi.org/10.1016/j.cell.2012.06.024

[85] Amaral, T., Sinnberg, T., Meier, F., Krepler, C., Levesque, M., Niessner, H., & Garbe, C. (2017). The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. European Journal of Cancer (Oxford, England), 73, 85–92. https://doi.org/10.1016/j.ejca.2016.12.010

[86] Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., Johnson, L. A., Robinson, J., Verhaak, R. G., Sougnez, C., Onofrio, R. C., Ziaugra, L., Cibulskis, K., Laine, E., Barretina, J., Winckler, W., Fisher, D. E., Getz, G., Meyerson, M., . . . Garraway, L. A. (2010). Integrative analysis of the melanoma transcriptome. Genome Research, 20(4), 413–427. https://doi.org/10.1101/gr.103697.109

[87] Pleasance, E., Titmuss, E., Williamson, L., Kwan, H., Culibrk, L., Zhao, E. Y., Dixon, K., Fan, K., Bowlby, R., Jones, M. R., Shen, Y., Grewal, J. K., Ashkani, J., Wee, K., Grisdale, C. J., Thibodeau, M. L., Bozoky, Z., Pearson, H., Majounie, E., . . . Marra, M. A. (2020). Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 1(4), 452–468. https://doi.org/10.1038/s43018-020-0050-6

[88] Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Mock, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., Gieldon, L., Möhrmann, L., Hanf, D., Teleanu, V., Heilig, C. E., Lipka, D. B., Allgäuer, M., Ruhnke, L., Laßmann, A., . . . Fröhling, S. (2021). Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discovery, 11(11), 2780– 2795. https://doi.org/10.1158/2159-8290.CD-21-0126

[89] Ulintz, P. J., Wu, W., & Gates, C. M. (2019). Bioinformatics analysis of whole exome sequencing data. Methods in Molecular Biology (Clifton, N.J.), 1881, 277–318. https://doi.org/10.1007/978-1- 4939-8876-1_21

[90] Bamshad, M. J., Ng, S. B., Bigham, A. W., Tabor, H. K., Emond, M. J., Nickerson, D. A., & Shendure, J. (2011). Exome sequencing as a tool for Mendelian disease gene discovery. Nature Reviews Genetics, 12(11), 745–755. https://doi.org/10.1038/nrg3031

[91] Wang, Z., Gerstein, M., & Snyder, M. (2009). RNA-Seq: A revolutionary tool for transcriptomics. Nature Reviews Genetics, 10(1), 57–63. https://doi.org/10.1038/nrg2484

[92] Ozsolak, F., & Milos, P. M. (2011). RNA sequencing: Advances, challenges and opportunities. Nature Reviews Genetics, 12(2), 87–98. https://doi.org/10.1038/nrg2934

[93] Pickrell, J. K., Gilad, Y., & Pritchard, J. K. (2012). Comment on “Widespread RNA and DNA sequence differences in the human transcriptome”. Science, 335(6074), 1302. https://doi.org/10.1126/science.1210484